154 related articles for article (PubMed ID: 36428951)
1. Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma.
Zeng Z; Liang Y; Shi J; Xiao L; Tang L; Guo Y; Chen F; Lin G
Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36428951
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
Front Genet; 2022; 13():838624. PubMed ID: 35928454
[TBL] [Abstract][Full Text] [Related]
3. A novel tumor mutation-related long non-coding RNA signature for predicting overall survival and immunotherapy response in lung adenocarcinoma.
Chen W; Liao C; Xiang X; Li H; Wu Q; Li W; Ma Q; Chen N; Chen B; Li G
Heliyon; 2024 Apr; 10(7):e28670. PubMed ID: 38586420
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma.
Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y
Front Surg; 2022; 9():860806. PubMed ID: 35937602
[TBL] [Abstract][Full Text] [Related]
5. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
6. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
7. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
Front Genet; 2022; 13():862741. PubMed ID: 35368663
[No Abstract] [Full Text] [Related]
8. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
9. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.
Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M
Front Genet; 2022; 13():951311. PubMed ID: 36406130
[No Abstract] [Full Text] [Related]
10. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
11. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
12. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
13. A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape.
Ma C; Li F; He Z; Zhao S
Front Surg; 2022; 9():1015263. PubMed ID: 36311939
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a novel prognostic model of inflammation-related gene signature of lung adenocarcinoma.
Luo D; Feng W; Ma Y; Jiang Z
Sci Rep; 2022 Aug; 12(1):14729. PubMed ID: 36042374
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
[TBL] [Abstract][Full Text] [Related]
16. Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma.
Hu J; Wang T; Chen Q
Transl Cancer Res; 2019 Aug; 8(4):1046-1064. PubMed ID: 35116848
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs.
Peng L; Ji J; Zhang C; Wu Z; Sun Y; Fan K; Du W; Liu A; Jiao W
J Thorac Dis; 2022 Oct; 14(10):3955-3974. PubMed ID: 36389299
[TBL] [Abstract][Full Text] [Related]
18. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma.
Zhuang J; Chen Z; Chen Z; Chen J; Liu M; Xu X; Liu Y; Yang S; Hu Z; He F
Respir Res; 2022 May; 23(1):123. PubMed ID: 35562727
[TBL] [Abstract][Full Text] [Related]
19. An
Han Y; Wong FC; Wang D; Kahlert C
Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
[TBL] [Abstract][Full Text] [Related]
20. A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer.
Jiao Y; Li S; Wang X; Yi M; Wei H; Rong S; Zheng K; Zhang L
Front Immunol; 2022; 13():929846. PubMed ID: 35990656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]